Pfizer vs Eli Lilly: Different Bets on Pharma M&A

By Trey Thoelcke Published May 11, 9:05AM EDT

Quick Read

Eli Lilly (LLY) has shown revenue growth from a position of strength while Pfizer (PFE) is still rebuilding from the COVID cliff.
For a retirement-focused investor, one may be more temping now but the other may be the stronger long-term franchise.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Eli Lilly wasn't one of them. Get them here FREE.

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Pfizer vs Eli Lilly: Different Bets on Pharma M&A — © XtockImages / iStock via Getty Images

Pfizer (NYSE: PFE | PFE Price Prediction) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story.

Blowout Quarter Meets a Methodical Rebuild

Lilly’s Q1 2026 revenue hit $19.799 billion, adjusted EPS came in at $8.55 against a $6.79 estimate, and management raised full-year revenue guidance to $82.0 billion to $85.0 billion. Mounjaro alone produced $8.662 billion, up 125%, and Zepbound added $4.160 billion. CEO David Ricks framed it bluntly: “2026 is off to a strong start…we also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly’s future growth through four acquisitions.”

Pfizer’s Q4 2025, by contrast, was a fix-the-foundation quarter. Revenue of $17.56 billion slipped 1.2% year over year, but the non-COVID portfolio grew 9% operationally. Eliquis, Vyndaqel, and Prevnar each posted roughly 10% growth. Comirnaty fell 33% and Paxlovid 70%, exactly the hole Albert Bourla is trying to plug.

Offensive Bolt-Ons Versus Defensive Big Bets

Lens	Eli Lilly	Pfizer
Core M&A bet	Orna, Centessa, Kelonia, Ajax plus $2.75B Insilico AI deal	$7.0B Metsera obesity buy, 3SBio license
Funding posture	Cash-rich, GLP-1 funded	$7.2B cost program by 2027
Forward P/E	34×	9×
Dividend yield	0.7%	6.7%

Lilly is buying capability from strength: AI drug discovery via Insilico’s Pharma.AI platform, plus an Nvidia AI co-innovation lab. Pfizer is buying revenue replacement, having entered obesity only after losing the Metsera bidding battle with Novo Nordisk and discontinuing its own oral GLP-1 danuglipron.

The Patent Cliff Decides Who Wins

The extreme macro shot of the injector pen makes the abstract concept of 'GLP-1 market dominance' tangible and high-stakes. The intense blue rim lighting creates a high-tech, futuristic feel that demands attention on mobile feeds.

The industry faces 190+ products losing exclusivity and over $300 billion in sales at risk by 2030. Pfizer’s own $1.5 billion loss-of-exclusivity hit in 2026 and 2026 EPS guide of $2.80 to $3.00 show the pressure. Vyndamax extension to 2031 and the recent Veppanu approval buy time. Lilly’s Foundayo FDA approval, the only anytime oral GLP-1, plus retatrutide Phase 3 wins extend the franchise well past the cliff.

Why Lilly Looks Stronger for a Retirement Portfolio Today

For a retirement-focused investor, the obvious temptation is Pfizer’s 6.7% yield and 3.1% year-to-date gain. But on the fundamentals, Lilly screens stronger by a wide margin. Pfizer’s M&A is reactive. Lilly’s is compounding. Lilly stock is down 11.8% year to date despite a guidance raise, which can be seen as an entry point. Polymarket traders priced a 100% probability of Lilly beating its $7.00 Q1 threshold, and the company delivered $8.55. It is better to pay 34 times earnings for the company writing the next decade’s playbook than nine times for one still patching the last one. If Mounjaro pricing in China collapses faster than expected, this may be worth a revisit. Until then, Lilly appears to be the stronger long-term franchise.

About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.